US-based bioengineering technology provider Genomatica has closed a $118m series C round led by pharmaceutical firm Novo.
Casdin Capital, Nicholas Investment Partners, Tenere Capital, Tharsis Capital and Viking Global Investors filled out the participants in the round.
Founded in 2000, Genomatica produces sustainable chemicals which leverage plant and waste-derived raw materials to replace traditional materials or chemicals.
Microbe engineering group Ginkgo Bioworks had taken part in a $90m round for the company in 2018 that was led by Casdin Capital and also backed by Viking Global Investors.
Waste processing firm Waste Management had contributed to a $45m round in March 2011 featuring VantagePoint Venture Partners, Bright Capital, Alloy Ventures, DFJ, Mohr Davidow Ventures and TPG Biotech. Genomatica filed for a $100m initial public offering in August the same year but later cancelled the attempt.
Chemical supplier Versalis chipped into Genomatica’s $41.5m series D round a year later, investing with Waste Management, Alloy Ventures, Draper Fisher Jurvetson, Mohr Davidow Ventures and VantagePoint Capital Partners. Its shareholders also include Batios Holdings and Iceland Genomics Ventures.
